Introduction

A shareholder rights plan, also known as a "poison pill", is one of the most effective defense tactics available to publicly traded corporations. A poison pill is designed to make the transaction being pursued by a hostile bidder extremely unattractive from an economic perspective, compelling the bidder to negotiate with the target's Board of Directors.

Generally, a poison pill issues rights to all existing shareholders, with the exception of the hostile suitor, to acquire stock of the target (or of the aggressor upon a subsequent merger) at prices significantly below market. These rights are triggered by certain specified events, such as the announcement of a cash tender offer or the acquisition by an outsider of a specified percentage of the target's shares. Thus, a poison pill is effective because it dilutes the economic interest of the hostile suitor in the target, making the transaction both economically unattractive and impractical if pursued on a hostile basis.

Mechanics of a Rights Plan

A typical rights plan follows a distinct sequence: adoption, distribution (if triggered), redemption, and expiration. Adoption of the plan only requires a vote by the Board of Directors. Typically, the Board approves an issue of one right for each outstanding share of its common stock. Once approved, each right entitles the holder, upon occurrence of certain events, to purchase common or participating preferred stock of the company ("flip-in") or common stock of the acquirer ("flip-over") at a predetermined exercise price. The rights initially are attached to and trade with the company's common stock. Currently, the most widely used poison pills are "call plans" that combine the following features:

Determining the Exercise Price

The exercise price is set by the Board with the help of its financial advisors. The setting of the exercise price is designed to neither put a transaction value on the company nor reflect an appropriate acquisition price. Rather, the exercise price is determined by estimating the long-term trading value of the company's common stock during the life of the rights plan. Usually, the exercise price is in the range of 3-5x the company's current stock price at the time of adoption, though multiples have risen recently due to generally depressed stock prices. The exercise price as a multiple of the company's stock price is higher for companies with high growth potential or companies where current operating performance is depressed, and it is lower for more established companies in mature industries. The development of an exercise price should not be based on the average of other companies' rights plans but, rather, on the characteristics of the company itself.

General Terms of "Call Plans"